Biotech News

Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026

Tempest Therapeutics (TPST)Tempest Therapeutics2026-07-15 11:00 ESTEarnings

Advancing a pipeline of in vivo CAR-T product candidates for oncology and immunology applications differentiated by CD7-targeted mRNA/LNP delivery approach Lead candidate TPST-4003 combines proprietary CD7-targeted mRNA/LNP delivery with a clinically validated dual-targeting CD19/BCMA CAR construct

Related news

TPSTTempest Therapeutics2026-07-21 11:00 EST

Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

RVMDRevolution Medicines2026-07-29 20:05 EST

Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026

REPLReplimune Group2026-06-29 12:00 EST

Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update

CHRSCoherus BioSciences, Inc.2026-08-05 20:28 EST

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

BMEABiomea Fusion2026-08-05 20:05 EST

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

ELVNEnliven Therapeutics2026-08-05 20:05 EST

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

ARGXArgenx2026-07-16 05:00 EST

argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026

KURAKura Oncology2026-08-05 11:30 EST

Kura Oncology to Report Second Quarter Financial Results

BMYBMYBristol-Myers Squibb Company2026-07-30 10:59 EST

Bristol Myers Squibb Reports Second Quarter Financial Results for 2026

View all latest news

Tempest Therapeutics

Tempest Therapeutics is an oncology company focused on small molecules and immunotherapy combinations for difficult cancers. Its investment case is driven by the idea that combination strategies can unlock differentiated responses in solid tumors.

Recent company news

TPSTTempest Therapeutics2026-07-21 11:00 EST

Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T

TPSTTempest Therapeutics2026-07-15 11:00 EST

Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026

TPSTTempest Therapeutics2026-06-04 20:37 EST

Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

TPSTTempest Therapeutics2026-05-29 12:00 EST

Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

TPSTTempest Therapeutics2026-05-14 20:15 EST

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

Stock data

Close: 0.90 USD
Market cap: 19.4M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States